

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8351913

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
INCARDA THERAPEUTICS, INC.	12/20/2023
RECEIVING PARTY DATA	
Name:	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT
Street Address:	345 PARK AVENUE SOUTH
Internal Address:	12TH FLOOR
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10010
PROPERTY NUMBERS Total: 24	
Property Type	Number
Patent Number:	10045939
Application Number:	18461958
Patent Number:	8974828
PCT Number:	US2010027740
Patent Number:	10668015
Patent Number:	11547663
Patent Number:	10010294
Patent Number:	10660578
PCT Number:	US2017016018
PCT Number:	US2019035565
Application Number:	16972362
Patent Number:	10744087
PCT Number:	US2019023569
Patent Number:	10441537
Application Number:	17739951
PCT Number:	US2018032092
Patent Number:	11007185
Patent Number:	11020384
Application Number:	17574901

PATENT

Property Type	Number
PCT Number:	US2020044291
Application Number:	17708732
Application Number:	18186668
PCT Number:	US2021064213
PCT Number:	US2022052294

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 212.318.6000

Email: JeffreyNegron@PaulHastings.com

Correspondent Name: JEFFREY NEGRON

Address Line 1: PAUL HASTINGS LLP

Address Line 2: 200 PARK AVENUE

Address Line 4: NEW YORK, NEW YORK 10166

NAME OF SUBMITTER: JEFFREY M. NEGRON

SIGNATURE: /s/ Jeffrey M. Negron

DATE SIGNED: 12/27/2023

Total Attachments: 11

source=InCarda - IPSA - PT#page1.tif

source=InCarda - IPSA - PT#page2.tif

source=InCarda - IPSA - PT#page3.tif

source=InCarda - IPSA - PT#page4.tif

source=InCarda - IPSA - PT#page5.tif

source=InCarda - IPSA - PT#page6.tif

source=InCarda - IPSA - PT#page7.tif

source=InCarda - IPSA - PT#page8.tif

source=InCarda - IPSA - PT#page9.tif

source=InCarda - IPSA - PT#page10.tif

source=InCarda - IPSA - PT#page11.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of December 20, 2023 by and between INCARDA THERAPEUTICS, INC. (“**Grantor**”) and DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (the “**Collateral Agent**”), as collateral agent for the Secured Note Holders, as such term is defined in the Security Agreement, dated on or about the date hereof, by and among the Grantor (as Debtor) and the Collateral Agent (as amended and/or restated from time to time, the “**Security Agreement**”).

RECITALS

A. Secured Note Holders hold senior secured convertible promissory notes (the “**Notes**”) issued by the Grantor in the amounts and manner set forth in that certain Note Purchase Agreement, dated as of December 20, 2023, by and among Grantor and Secured Note Holders (as the same may be amended, modified or supplemented from time to time, the “**Purchase Agreement**”). Capitalized terms used herein are used as defined in the Security Agreement.

B. Pursuant to the terms of the Security Agreement (the “**Security Agreement**”, and together with the Purchase Agreement and related agreements, instruments, certificates, filings and documents, the “**Transaction Documents**”), Grantor has granted to Collateral Agent, for the benefit of the Secured Note Holders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as defined in the Security Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Transaction Documents, Grantor hereby covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Transaction Documents, Grantor grants and pledges to Collateral Agent, for the benefit of the Secured Note Holders, a security interest in all of Grantor’s right, title and interest in, to and under its registered intellectual property (including, without limitation, any registered copyrights, patents and trademarks, and pending registrations or filings for any of the foregoing) listed on Exhibit A hereto (the “**Intellectual Property Collateral**”), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof. Notwithstanding the foregoing, the Intellectual Property Collateral does not include any “intent to use” trademarks at all times prior to the first use thereof, whether by the actual use thereof in commerce, the recording of a statement of use with the United States Patent and Trademark Office or otherwise; provided, that upon submission and acceptance by the United States Patent and Trademark Office of an amendment to allege use of an intent-to-use trademark

application pursuant to 15 U.S.C. Section 1060(a) (or any successor provision) such intent-to-use application shall constitute Intellectual Property Collateral.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Secured Note Holders, under the Security Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Security Agreement and the other Transaction Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Secured Note Holders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Transaction Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement and the Transaction Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including any Secured Note Holder, of any or all other rights, powers or remedies.

[Balance of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

INCARDA THERAPEUTICS, INC.

DocuSigned by:


By: 1D86E200C2B24E9
Name: Carlos Schuler
Title: Chief Executive Officer

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

COLLATERAL AGENT:

**DEERFIELD MANAGEMENT COMPANY, L.P.
(SERIES C)**

By: Flynn Management LLC
General Partner

By:  _____
Name: David Clark
Title: Authorized Signatory

Address:
Deerfield Management Company, L.P.
345 Park Ave South
New York, NY 10010
Attn: Lawrence Atinsky
Phone: (212) 583-7286
Email: legalnotice@deerfield.com

Exhibit A

Intellectual Property Collateral

Patents:

701 Family: UNIT DOSES, AEROSOLS, KITS, AND METHODS FOR TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION								
Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-701	US	101	PRO	Expired	61/210382	18-Mar-2009		
46093-701	US	102	PRO	Expired	62/504292	10-May-2017		
46093-701	US	301	CON	ISSUED	14/632252	26-Feb-2015	10045939	14-Aug-2018
46093-701	US	302	CON	Abandoned	16/013165	20-Jun-2018		
46093-701	US	303	CON	Abandoned	16/013178	20-Jun-2018		
46093-701	US	304	CON	Abandoned	16/172456	26-Oct-2018		
46093-701	US	305	CON	Abandoned	17/095296	11-Nov-2020		
46093-701	US	306	CON	Abandoned	17/514674	29-Oct-2021		
46093-701	US	307	CON	Abandoned	17/836765	09-Jun-2022		
46093-701	US	308	CON	Abandoned	18/097566	17-Jan-2023		
46093-701	US	309	CON	Pending	18/461958	06-Sep-2023		
46093-701	US	501	CIP	Abandoned	16/789151	12-Feb-2020		
46093-701	US	502	CIP	Abandoned	16/789156	12-Feb-2020		
46093-701	US	831	PCT	ISSUED	13/257249	16-Sep-2011	8974828	10-Mar-2015
46093-701	WO	601	ORD	30 MO DONE	PCT/US2010/027740	18-Mar-2010		
46093-701	EPO	611	PCT	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	EPO	6111	DIV	Allowed	19176305.1	18-Mar-2010		
46093-701	EPO	6112	DIV	Published	19176272.3	18-Mar-2010		
46093-701	Germany	621	EPP	Granted	10754091.6	18-Mar-2010	602010060046.7	17-Jul-2019

46093-701	France	631	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	United Kingdom	641	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Austria	650	EPP	Granted	10754091.6	18-Mar-2010	E-1155182	17-Jul-2019
46093-701	Belgium	651	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Switzerland	653	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Denmark	656	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Spain	658	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Finland	659	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Ireland	662	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Italy	663	EPP	Granted	10754091.6	18-Mar-2010	502019000083348	17-Jul-2019
46093-701	Luxembourg	664	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Netherlands	666	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Sweden	669	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Australia	681	PCT	Granted	2010226613	18-Mar-2010	2010226613	07-Nov-2013
46093-701	Australia	6811	DIV	Granted	2013248242	18-Mar-2010	2013248242	01-Dec-2016
46093-701	Australia	6812	DIV	Granted	2016256776	18-Mar-2010	2016256776	26-Jul-2018
46093-701	Canada	701	PCT	Granted	2755809	18-Mar-2010	2755809	18-Feb-2014
46093-701	Canada	7011	DIV	Granted	2835771	18-Mar-2010	2835771	24-Jan-2017
46093-701	Japan	761	PCT	Abandoned	2012-500945	18-Mar-2010		
46093-701	Japan	7611	DIV	Abandoned	2015-149197	18-Mar-2010		
46093-701	Japan	7612	DIV	Published	2017-123029	18-Mar-2010		
46093-701	Japan	7613	DIV	Granted	2018-204914	18-Mar-2010	6715305	10-Jun-2020
46093-701	Japan	7614	DIV	Granted	2019-162836	18-Mar-2010	7071949	11-May-2022
46093-701	Hong Kong	891	REP	Granted	12107719.1	18-Mar-2010	1166952	17-Apr-2020
46093-701	Hong Kong	8911	REP	Published	42020004095.4	18-Mar-2010		

46093-701	Hong Kong	8912	REP	Published	42020004097.0	18-Mar-2010		
46093-701	Norway	901	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
46093-701	Poland	941	EPP	Granted	10754091.6	18-Mar-2010	2413902	17-Jul-2019
702 Family: UNIT AEROSOL DOSES FOR ANTICOAGULATION Owners: InCarda Therapeutics, Inc.; The Regents of the University of California								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-702	US	101	PRO	Expired	61/615587	26-Feb-2012		
46093-702	US	102	PRO	Expired	61/806254	28-Mar-2013		
46093-702	US	103	PRO	Expired	62/105644	20-Jan-2015		
46093-702	WO	601	ORD	Expired	PCT/US2016/014126	20-Jan-2016		
46093-702	EP	611	PCT	Withdrawn	16706921.0	20-Jan-2016		
46093-702	GB	641	PCT	Granted	1621632.7	20-Jan-2016	201621632	01-Feb-2017
46093-702	US	831	PCT	Issued	15/317282	08-Dec-2016	10668015	02-Jun-2020
46093-702	US	301	CON	Issued	16/890264	02-Jun-2020	11547663	10-Jan-2023
46093-702	US	302	CON	Abandoned	18/151865	09-Jan-2023		
46093-702	HK	891	REP	Withdrawn	17109083.0	20-Jan-2016		
706 Family: COMBINING ELECTRONIC MONITORING WITH INHALED PHARMACOLOGICAL THERAPY TO MANAGE ATRIAL ARRHYTHMIAS INCLUDING ATRIAL FIBRILLATION Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-706	US	101	PRO	Expired	62/289473	01-Feb-2016		
46093-706	US	201	ORD	ISSUED	15/422053	01-Feb-2017	10010294	03-Jul-2018
46093-706	US	301	CON	ISSUED	15/928851	22-Mar-2018	10660578	26-May-2020
46093-706	WO	601	ORD	30 MO DONE	PCT/US2017/016018	01-Feb-2017		
46093-706	EPO	611	PCT	Published	17748062.1	01-Feb-2017		
46093-706	Israel	731	PCT	Granted	260335	01-Feb-2017	260335	02-Sep-2023
46093-706	India	741	PCT	Published	201817031854	01-Feb-2017		
46093-706	Korea	771	PCT	Published	10-2018-7025356	01-Feb-2017		

46093-706	Russia	811	PCT	Granted	2018131232	01-Feb-2017	2768748	24-Mar-2022
46093-706	Singapore	821	PCT	Granted	11201805788W	01-Feb-2017	11201805788W	24-Dec-2020
46093-706	Hong Kong	891	REP	Published	19119614.6	01-Feb-2017		
707 Family: METHODS FOR DIAGNOSING BRUGADA SYNDROME USING A NEBULIZED AEROSOLMETHODS FOR DIAGNOSING BRUGADA SYNDROME USING A NEBULIZED AEROSOL Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-707	US	103	PRO	Expired	62/680746	05-Jun-2018		
46093-707	WO	601	ORD	30 MO DONE	PCT/US2019/035565	05-Jun-2019		
46093-707	US	831	PCT	TO BE ABAND	16/972362	04-Dec-2020		
46093-707	Hong Kong	891	REP	TO BE ABAND	62021040386.6	05-Jun-2019		
709 Family: A NOVEL METHOD TO SLOW VENTRICULAR RATE DURING EPISODES OF ATRIAL FIBRILLATION BY DELIVERING MEDICATIONS VIA ORAL OR INTRANASAL INHALATION Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-709	US	101	PRO	EXPIRED	62/646528	22-Mar-2018		
46093-709	US	201	ORD	ISSUED	16/361649	22-Mar-2019	10744087	18-Aug-2020
46093-709	WO	601	ORD	30 MO DONE	PCT/US2019/023569	22-Mar-2019		
46093-709	EPO	611	PCT	Published	19772485.9	22-Mar-2019		
710 Family: TREATING HEART CONDITIONS BY PULMONARY ADMINISTRATION Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-710	US	201	ORD	ISSUED	15/976516	10-May-2018	10441537	15-Oct-2019
46093-710	US	301	CON	Abandoned	16/192337	15-Nov-2018		
46093-710	US	302	CON	Abandoned	16/533348	06-Aug-2019		
46093-710	US	303	CON	Published	17/739951	09-May-2022		
46093-710	WO	601	ORD	30 MO DONE	PCT/US2018/032092	10-May-2018		
46093-710	EPO	611	PCT	Published	18799041.1	10-May-2018		
46093-710	Australia	681	PCT	Pending	2018266199	10-May-2018		

46093-710	Canada	701	PCT	Published	3060702	10-May-2018		
46093-710	China	711	PCT	Published	201880046226.1	10-May-2018		
46093-710	Israel	731	PCT	Pending	270407	10-May-2018		
46093-710	Japan	761	PCT	Abandoned	2019-562284	10-May-2018		
46093-710	Japan	7611	DIV	Published	2023-071974	10-May-2018		
46093-710	Korea	771	PCT	Published	10-2019-7036576	10-May-2018		
46093-710	Singapore	821	PCT	Pending	11201910246U	10-May-2018		
46093-710	Singapore	8211	DIV	Published	10202112514W	10-May-2018		
46093-710	Hong Kong	891	REP	Published	62020015303.4	10-May-2018		
46093-710	Hong Kong	892	RCN	Published	62020015032.9	10-May-2018		
713 Family: ANTIARRHYTHMIC FORMULATION Owner: InCarda Therapeutics, Inc.								
Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-713	US	101	PRO	Expired	62/881689	01-Aug-2019		
46093-713	US	201	ORD	ISSUED	16/901909	15-Jun-2020	11007185	18-May-2021
46093-713	US	202	ORD	ISSUED	16/901941	15-Jun-2020	11020384	01-Jun-2021
46093-713	US	301	CON	Published	17/574901	13-Jan-2022		
46093-713	WO	601	ORD	30 MO DONE	PCT/US2020/044291	30-Jul-2020		
46093-713	EPO	611	PCT	Published	20848179.6	30-Jul-2020		
46093-713	Australia	681	PCT	Granted	2020323594	30-Jul-2020	2020323594	19-May-2022
46093-713	Australia	6811	DIV	Pending	2022202842	30-Jul-2020		
46093-713	Canada	701	PCT	Published	3139748	30-Jul-2020		
46093-713	China	711	PCT	Published	202080052432.0	30-Jul-2020		
46093-713	Israel	731	PCT	Granted	290088	30-Jul-2020	290088	02-Sep-2023
46093-713	Israel	7311	DIV	Pending	303094	30-Jul-2020		
46093-713	India	741	PCT	Published	202217005447	30-Jul-2020		
46093-713	Japan	761	PCT	Granted	2022-506507	30-Jul-2020	7190077	06-Dec-2022

46093-713	Japan	7611	DIV	Published	2022-193405	30-Jul-2020		
46093-713	Korea	771	PCT	Granted	10-2022-7003421	30-Jul-2020	10-2491733	19-Jan-2023
46093-713	Korea	7711	DIV	Published	10-2023-7001970	30-Jul-2020		
46093-713	Singapore	821	PCT	Pending	11202113226Q	30-Jul-2020		
46093-713	Hong Kong	891	REP	Published	62022064188.5	30-Jul-2020		
46093-713	Hong Kong	892	RCN	Published	62022056020.0	30-Jul-2020		

719 Family: KITS AND METHODS FOR INDUCTION OF CARDIOVERSION IN SUBJECTS WITH ATRIAL ARRHYTHMIAS
Owner: InCarda Therapeutics, Inc.

Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-719	US	101	PRO	Expired	63/127089	17-Dec-2020		
46093-719	US	102	PRO	EXPIRED	63/153492	25-Feb-2021		
46093-719	US	301	CON	Allowed	17/708732	30-Mar-2022		
46093-719	US	302	CON	Published	18/186668	20-Mar-2023		
46093-719	WO	601	ORD	30 MO DONE	PCT/US2021/064213	17-Dec-2021		
46093-719	EPO	611	PCT	Published	21907959.7	17-Dec-2021		
46093-719	Canada	701	PCT	Published	3200432	17-Dec-2021		
46093-719	China	711	PCT	Published	202180093915.X	17-Dec-2021		
46093-719	Japan	761	PCT	Pending	2023-537307	17-Dec-2021		

724 Family: INHALED THERAPY FOR ATRIAL ARRHYTHMIA
Owner: InCarda Therapeutics, Inc.

Case Number	Country	Sub Case	Case Type	Status	Application Number	Filing Date	Patent Number	Issue Date
46093-724	US	101	PRO	Expired	63/287921	09-Dec-2021		
46093-724	WO	601	ORD	Published	PCT/US2022/052294	08-Dec-2022		

Trademarks:

INCARDA®
INRHYTHM®
MYRITMY™